Veristat Announces Global Cell and Gene Therapy Center of Excellence
22.10.2020 11:13:00 EEST | Business Wire | Press release
Cell and gene therapies represent the next great wave of therapeutic innovation and have led to the development of promising therapies worldwide.
Veristat, a scientific minded clinical research organization, announced today the launch of their Global Cell and Gene Therapy Center of Excellence (COE). The COE comprises a multi-disciplinary team of scientific experts who are adept at strategy and execution across this complex clinical development pathway. Veristat’s experience supporting these unique programs in the Americas and Europe enables them to implement impactful advisory and tactical services to support the challenging decisions required to advance a cell and gene therapy to market. Leveraging the learnings from the support of numerous client cell and gene therapy programs, including the first gene therapy approved in Europe, the Global COE will serve as a powerhouse for sponsors and as a mechanism to share insights, successful strategies, and best practices.
“We understand how high the stakes are with cell and gene therapy programs,” stated Alecia Barbee, Executive Vice President, Operations at Veristat, “and that nothing is standard about the therapies, the studies or the regulatory processes in this specialized area. Veristat has successfully supported more than 100 cell and gene therapy projects across the entire clinical development life-cycle, and with the launch of our center of excellence, we are formalizing our processes to assist sponsors around the globe to bring these advanced therapies to market quickly.”
Every cell or gene therapy is unique, often coming with a complicated regulatory approval process and unique therapeutic challenges. Even the best therapeutic may not reach patients who need it if the study design and execution are not optimal. Veristat offers tailored solutions across the entire clinical development pathway to combat these challenges, including:
- The ability to develop your therapeutic with accelerated approval pathways and/or special designations
- A review of operational aspects of the protocol and feedback on any potential obstacles/challenges that could impact the protocol execution at the clinical research sites
- Novel strategies including implementation of a centralized site model and remote monitoring with direct-to-patient capabilities
- Expertise in logistics and handling of live cellular material
- Development of bespoke regulatory strategies for the type of cell and gene therapy and the unmet clinical need acceptable to the regulatory agencies
- Long-term follow-up strategies to meet global regulatory requirements
“The challenges of developing cell and gene therapies requires a committed and experienced partner,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Cell and gene therapies offer uniquely curative potential for disorders that are intractable to other treatment modalities. They can save lives. The challenge now is to scale the opportunity they offer to their full potential. Our years of experience in this specialized area and reputation for success will make Veristat the CRO of choice for small and medium biopharmaceutical companies who want to bring their cell or gene therapies to patients worldwide.”
About Veristat:
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005181/en/
Contact information
Veristat Contact:
Lauren Willis, Marketing Manager
marketing@veristat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Third-Party EPDs Confirm C-Crete Cement Cuts Embodied Carbon by up to 95% — and It’s Already Being Poured Commercially28.7.2026 15:05:00 EEST | Press release
C-Crete Technologies has published two Environmental Product Declarations (EPDs) verifying that its cements cut embodied carbon by up to 95% versus conventional portland cement. C-Crete’s technology converts a broad range of natural rocks and industrial by-products into cementitious binders with no clinker and no kiln, so production is inherently decentralized — and it is already being poured in commercial concrete today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728132467/en/ Representative C-Crete's project portfolio. More than 4000 tons of C-Crete's ultra-low carbon concrete have been poured in different cities since 2023. C-Crete's oldest pour is more than 3 years old, with no sign of degradation or cracking. Verified performance, not projections C-Crete’s clinker-free Ultra Low Carbon Cement (NRMCA EPD 20353) reports a global warming potential of just 43.1 kg CO2-eq per metric ton — roughly 95% below the 919 kg
Nine in 10 LPs More Likely to Commit to Funds Using Leverage When Disclosure is Clear28.7.2026 15:00:00 EEST | Press release
Fund-level leverage and liquidity tools have moved from specialist financing techniques to mainstream private capital infrastructure, according to new research from CSC, the leading provider of global business administration and compliance solutions. The findings show that limited partners (LPs) are increasingly open to the use of these tools when disclosure is clear, but general partners (GPs) face growing pressure to prove that the operating model behind them is controlled, transparent, and investor-ready. CSC¹ surveyed 300 GPs and 200 LPs across North America, Europe, the U.K., and Asia Pacific. The report, Future Private Capital CFO 2026: How CFOs are becoming the architects of operational trust, examines how fund finance, liquidity management, reporting, outsourcing, cybersecurity, and AI governance are reshaping the role of the private capital CFO. The findings show the market has moved beyond a simple debate about whether fund-level leverage should be used. Instead, LP focus is
Omilia Appoints David Ogden as VP of Revenue Operations28.7.2026 15:00:00 EEST | Press release
Omilia, a global leader in Self-Learning Agentic CX, today announced the appointment of Dave Ogden as Vice President of Revenue Operations. Ogden will be responsible for scaling Omilia’s global revenue operations function spanning sales operations, forecasting, and commercial execution as the company accelerates growth across its key markets. In this role, Ogden will design and operate the revenue infrastructure that connects sales, marketing, and customer success, including forecasting, pipeline management, and deal desk operations. He joins as Omilia expands its direct and partner-led go-to-market across the US, Europe, Latin America and Australia, and will play a central role in ensuring that growth scales in a disciplined, data-driven way. Ogden brings more than 15 years of enterprise SaaS revenue and commercial operations experience. He spent nine years at Five9, progressing through a series of senior roles including VP of Strategy, Planning and Growth, where he led the build-out
B-Secur and CSEM Partner to Bring Clinically-Validated Heart Monitoring to Health Wearables28.7.2026 15:00:00 EEST | Press release
CSEM, the Swiss-based technology innovation centre, and B-Secur, a leader in advanced biosensing technology, today announced a partnership to bring clinically-validated heart monitoring capability to health wearables. The collaboration pairs CSEM's 25+ years of leadership in PPG-based vital signs monitoring with B-Secur's multiple FDA-cleared ECG algorithms and analytics, offering device manufacturers and digital health companies a route to integrating more accurate, market-ready heart monitoring into their products — for applications including remote patient monitoring, cardiovascular health, and chronic disease management. “By combining CSEM’s expertise in photoplethysmography-based vital signs monitoring with B-Secur’s ECG analytics, we are enabling a new class of multimodal sensing solutions that deliver clinically relevant insights. This partnership reflects our commitment to translating cutting-edge sensing and algorithm technologies into real-world healthcare applications.” Jose
ExaGrid Releases Version 8.128.7.2026 15:00:00 EEST | Press release
ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced the release of ExaGrid software version 8.1. The latest version includes: Support for Cohesity DataProtect Uses S3 protocol. Supports Cohesity Cloud Archive Direct. ExaGrid further deduplicates Cohesity deduplicated data, cutting the storage footprint in half. ExaGrid works with Cohesity NetBackup for mixed NetBackup and DataProtect environments. NFS encrypted over the wire Available for backup apps that support NFS encryption over the wire. ExaGrid already supports encryption over the wire with other protocols such as the Veeam Data Mover, CIFS, and S3. Share Quota ExaGrid already tracks how much data is going into each share. Now, a Managed Service Provider (MSP) can set a quota to match what the customer contract is. The MSP can set the share quota to match the amount in the co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
